Clinical Trial: NCT03464942
Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Peter MacCallum Cancer Centre, Australia |
| Information Provided By: | Peter MacCallum Cancer Centre, Australia |
| Last Update Posted: | 2023-07-19 |
Study Overview
Brief Summary
This is a multi-centre, open label, phase 2, randomised controlled trial of patients with advanced triple negative breast cancer (TNBC) who have received no more than one line of chemotherapy (not including neoadjuvant or adjuvant therapy) who will be randomised to be treated with SABR 20Gy in 1# followed by atezolizumab or SABR 24Gy in 3# followed by atezolizumab.
Official Title
A Randomised Phase II Trial Comparing the Efficacy of Single-fraction or Multi-fraction SABR (Stereotactic Ablative Body Radiotherapy) With AteZolizumab in Patients With Advanced Triple nEgative Breast Cancer
Conditions
Breast Cancer
Intervention / Treatment
- Radiation: SABR
- Drug: Atezolizumab
Other Study ID Numbers
- 17/013
Start Date (Actual)
2018-08-01
Primary Completion Date (Actual)
2023-06-22
Study Completion Date (Actual)
2023-06-22
Enrollment (Actual)
54
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Peter MacCallum Cancer Centre, Australia |
| Information Provided By: | Peter MacCallum Cancer Centre, Australia |
| Last Update Posted: | 2023-07-19 |
Study Overview
Brief Summary
This is a multi-centre, open label, phase 2, randomised controlled trial of patients with advanced triple negative breast cancer (TNBC) who have received no more than one line of chemotherapy (not including neoadjuvant or adjuvant therapy) who will be randomised to be treated with SABR 20Gy in 1# followed by atezolizumab or SABR 24Gy in 3# followed by atezolizumab.
Official Title
A Randomised Phase II Trial Comparing the Efficacy of Single-fraction or Multi-fraction SABR (Stereotactic Ablative Body Radiotherapy) With AteZolizumab in Patients With Advanced Triple nEgative Breast Cancer
Conditions
Breast Cancer
Intervention / Treatment
- Radiation: SABR
- Drug: Atezolizumab
Other Study ID Numbers
- 17/013
Start Date (Actual)
2018-08-01
Primary Completion Date (Actual)
2023-06-22
Study Completion Date (Actual)
2023-06-22
Enrollment (Actual)
54
Study Type
Interventional
Phase
Phase 2